clinical trial · NCT07002177
A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
Forward Pharmaceuticals Co., Ltd.·phase2·recruiting·n = 196
Metastatic Breast CancerBreast Cancer Stage IBreast Cancer Stage IILocally Advanced Breast Cancer (LABC)ER+ Breast CancerFWD1802Palbociclib 125mgRibociclib 200Mg Oral TabletAbemaciclib 150 MGEverolimus 10 mg
brief summary
This is a Study to Evaluate the Efficacy and Safety of Multiple Combination Therapies with FWD1802 in Subjects with ER-positive/HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer
started
Jun 1, 2025
primary completion
May 1, 2028
completion
Nov 1, 2028
last updated
Jan 7, 2026
official title
An Open-label, Multicenter, Phase Ib/II Clinical Study to Evaluate the Safety and Efficacy of Multiple Combination Therapies With FWD1802 in Subjects With ER-positive/HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol